CompletedPhase 2NCT00678119
Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment
Studying Acquired cystic disease-associated renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Argos Therapeutics
- Principal Investigator
- Fred MiesowiczArgos Therapeutics
- Intervention
- AGS-003(biological)
- Enrollment
- 25 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2008 – 2012
Study locations (14)
- City of Hope, Duarte, California, United States
- UCLA, Los Angeles, California, United States
- The Urology Center of Colorado, Denver, Colorado, United States
- Emory University, Atlanta, Georgia, United States
- The Indiana University Cancer Center, Indianapolis, Indiana, United States
- University of Iowa, Iowa City, Iowa, United States
- University of Kansas Hospital, Kansas City, Kansas, United States
- University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
- Carolina's Medical Center / Blumenthal Cancer Center, Charlotte, North Carolina, United States
- Barrett Cancer, Cincinnati, Ohio, United States
- CORTPA, Dallas, Texas, United States
- Urology of Virginia-Sentara Medical Group, Norfolk, Virginia, United States
- Princess Margaret Hospital, Toronto, Ontario, Canada
- Jewish General Hospital, Montreal, Quebec, Canada
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00678119 on ClinicalTrials.govOther trials for Acquired cystic disease-associated renal cell carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06882486Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic TherapyInstitut Paoli-Calmettes
- RECRUITINGPHASE1NCT07517198Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid TumorsExscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
- RECRUITINGNANCT06907095Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk IndividualsGustave Roussy, Cancer Campus, Grand Paris
- RECRUITINGNANCT07461090Laparoscopic Versus Open Nephrectomy : Clinical Effectivness and Cost AnalysisMenoufia University
- RECRUITINGNANCT07402109CBCT Guided Markerless SBRT for Renal Cell CancerErasmus Medical Center
- RECRUITINGPHASE1NCT07195682A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)Bristol-Myers Squibb
- RECRUITINGPHASE1NCT07006688A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal ImpairmentServier Bio-Innovation LLC
- RECRUITINGPHASE1, PHASE2NCT07219576Retifanlimab and Ruxolitinib In Solid MalignanciesUniversity of California, San Diego
See all trials for Acquired cystic disease-associated renal cell carcinoma →